JYP-0035

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are:
* What is the safety profile of JYP0035 when administered to these patients?
* How does JYP0035 capsule behave in the body pharmacokinetically?
Participants will:
* Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1).
* Continue with the identified dose in the dose-expansion phase (PART-2).
As this is a single-arm study, there is no comparison group.

考察中国健康成人参与者单次口服JYP0035胶囊后的药代动力学特征；评价空腹状态下不同处方制剂JYP0035胶囊的相对生物利用度。考察中国健康成人参与者单次口服JYP0035胶囊后的安全性。